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Abstract 
A synthetic peptide corresponding to the N-terminal amino acid residues of stanniocalcin (STC1-20) and including a region that is 
known to be an active site in teleosts was prepared and tested for its effects on the metabolism of mammalian bone in vitro. STC1-20 
( 1 0 - J °  10-12 M) inhibited increases in the number of tartrate-resistant acid phosphatase-positive, multinucleated cells promoted by an 
N-terminal fragment of human parathyroid hormone (hPTH1-34) in cultures of murine hemopoietic ceils. STC 1-20 also slightly decreased 
the rate of loss of radioactivity from calvariae of fetal rats that had been prelabeled with 45Ca, both with and without stimulation by 
hPTH1-34. The accumulation of cAMP induced by hPTH1-34 in ROS 17/2.8-5 cells was suppressed by STC1-20 (10- I°-10- 12 M). 
Treatment with STCI-20 (10 -~ -10  - 13 M) caused increases of the rate of incorporation of [3H]proline into the collagenase-digestible 
protein of calvariae in newborn mice. From these results, it appears that STC1-20 has diverse effects on the metabolism of mammalian 
bone, causing a biphasic response. Such effects have not been observed with intact stanniocalcin or with materials from the corpuscles of 
Stannius and they are also different from the effects of hPTH1-34. 
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1. Introduction 
The predominant hypocalcemic hormone in bony fishes 
is stanniocalcin (STC), referred to previously as hypocal- 
cin or teleocalcin [1-3]. S, TC is synthesized and secreted 
by the corpuscles of  Stannius (CS), which are located on 
the mesonephric kidney [ l -3] .  The complete amino acid 
sequence of  STC has been reported for Australian eel [4] 
and coho salmon [5]. There is a high degree of  similarity 
between the sequences, in particular, among the N-termi- 
nal amino acid residues [3,6]. STC is a homodimeric 
glycoprotein with a molecular weight of approx. 50-kDa 
[1-3,6] and it exhibits no similarities to calcitonin or to 
parathyroid hormone (PTH) in terms of  amino acid se- 
quence [4]. The target organs of  STC appear to be the 
intestine [6] and the gills [7], which play an important role 
in calcium regulation in teleosts. 
Possible biological functions for compounds of  the CS 
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and STC in mammals have been discussed [8-13]. Serum 
levels of calcium and magnesium were increased in rats 
after an intraperitoneal injection of  an extract of  eel CS [9]. 
A PTH-like molecule in eel plasma was identified from its 
cross-reactivity with an antiserum against bovine PTH 
(bPTH) and the immunoreactive substance was no longer 
detectable after removal of  the CS [10]. The PTH-like 
substance was detected in all cells of  the eel CS by 
immunocytochemistry with an antiserum against bPTH 
[1 1]. In other studies, administration (i.p.) to rats of  an 
extract of  eel CS resulted in the activation of  osteoclastic 
bone resorption at the periosteum of the femur [9]. A bone 
resorption assay using organ cultures of fetal bones re- 
vealed that extracts of  eel CS [9] and of  trout CS [12], as 
well as purified trout STC [13], stimulated the release of 
45Ca in a manner that resembled the release of  45Ca in 
response to stimulation by bPTH. However, Stern et al. 
[13] reported that pure STC from salmon did not consis- 
tently stimulate bone resorption in a variety of rodent 
bone-culture systems and that it had limited PTH-like 
activity, if any, on calcium metabolism in mammalian 
system. 
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Some researchers have reported the activities of frag- 
ments of the STC molecule in vivo [14-17]. In fish, it has 
been found that an N-terminal peptide fragment of eel 
[15,16] and salmon [15] STC has an inhibitory effect on 
whole-body calcium uptake, with the effect resembling 
that of the intact molecule. There is no agreement about 
the function of the C-terminal region [ 15-17]. The actions 
of six peptide fragments of eel STC 
and an effect on plasma potassium 
with either the N-terminal region or 
ment of eel STC [14]. 
were tested in sheep, 
levels was observed 
a mid-sequence frag- 
Identification of the active site of the STC molecule in 
mammalian systems should help to clarify the actions of 
STC in mammals, as well as the relationship between STC 
and PTH. The present study was, therefore designed as an 
attempt to characterize the effects of a synthetic N-termi- 
nal fragment of chum salmon STC, which includes the 
region that functions as the active site in fish, on the 
PTH-sensitive aspects of the metabolism of mammalian 
bone in vitro. 
2. Mater ia l s  and  m e t h o d s  
2.1. Synthesis of STC1-20 
Synthetic STC1-20 from chum salmon (Fig. 1) was 
prepared by the solid-phase BOC-polystyrene method us- 
ing an amino acid synthesizer (430A; Applied Biosystems, 
Foster City, CA). The peptide was cleaved from the resin 
by treatment with anhydrous hydrogen fluoride and the 
crude peptide was purified by preparative reverse-phase 
HPLC. The homogeneity of the preparation of the purified 
peptide was checked with an amino acid sequencer (PSQ- 1 ; 
Shimadzu, Japan). 
2.2. Generation of  osteoclast-like cells in bone marrow 
cultures 
The present method was based on the method reported 
by Takahashi et al. [18]. Marrow cells of tibiae from 
7-week-old ddY mice were collected, washed and sus- 
pended in MEM-c~ medium (Gibco, Grand Island, NY) 
supplemented with 10% fetal calf serum (FCS; Gibco). 
The suspension was divided among the wells of a 24-well 
plate and incubated with vehicle, as a control, or with 
various concentrations of STC1-20 and/or  an N-terminal 
fragment of human PTH (hPTH1-34; Peninsula Laborato- 
ries, Belmont, CA) for 8 days. After tartrate-resistant acid 
phosphatase (TRAP) staining, TRAP-positive multinucle- 
ated cells (TRAP + MNCs) were counted. 
2.3. Calvarial bone-resorption assay 
Pregnant Sprague-Dawley rats were injected subcuta- 
neously with 45Ca at a dose of 3.7 MBq per rat (0.37-1.5 
GBq/mg Ca; Amersham Japan, Japan) on the 18th day of 
gestation. On the following day, two calvariae from fetuses 
were selected randomly and precultured in each well of a 
24-well plate in Fitton-Jackson modified BGJb medium 
(Gibco) supplemented with 2 mg/ml  bovine serum albu- 
min (BSA; Sigma, St Louis, MO) for 24 h. The bones 
were then transferred to fresh medium that contained test 
samples, as described above, and incubated for an addi- 
tional 2 -4  days. The extent of bone resorption was calcu- 
lated as release of 45Ca, expressed as the percentage of 
original total radioactivity of the bones (sum of the ra- 
dioactivity of the medium and the bones), as described 
elsewhere in detail [19]. 
2.4. Production of cAMP in ROS17/2.8-5 cells 
ROSl7/2.8-5 cells derived from a rat osteosarcoma 
(Riken Cell Bank, Japan) were grown in Ham's F-12 
medium (Gibco) with 10% FCS. The cells were subcul- 
tured at weekly intervals and were then placed in the wells 
of a 48-well plate. When the cells reached confluence, they 
were preincubated with same medium plus 0.3% BSA and 
0.1 mM isobutylmethylxanthine (Sigma) as described in a 
previous report [20]. Test samples were added to the cells 
which were incubated for 5 min further. The reaction was 
stopped by removal of the medium by suction and the 
le ze  
Chum sa lmon  a H-Phe-Ser-•r•-A•n-Ser-Pr•-Ser-Asp-••1-A••-Arg-Cys-Leu-Asn-G•y-A1•-Leu-Asp-V••-G•y- 
Sockeye  salmon b . . . . . . . . . . . . . . . . . . . .  
Coho  sa lmon  C Se r  . . . . . . . . . . . . . .  A l a  - - 
Ra inbow  t r o u t  d Set - - /G lu  . . . . . . . . . .  A l a  - - 
Aus t r a l i an  eel  • - A l a  Se t  . . . . . . . . . . . . .  G in  - - 
30  
Cys-Gly-Thr-Phe-Ala-Cys-Leu-Glu- X -Se r -Th r -Cys -Asp -  
. . . . . . . .  Asn  . . . .  
. . . . . . . .  Asn  . . . .  
. . . . . . . .  X - 
Ser A lo  . . . .  Asp Asn - Asn 
Fig. 1. Comparison of the N-terminal sequences of STC from salmon, trout and eel. The differences from the sequence of STC from chum salmon are 
indicated by the appropriate amino acid substitutions. The synthetic peptide based on STC from chum salmon is underlined, a Suudell et al. [6], b Wagner 
et al. [3], c Wagner et al. [5], d Lafeber et al. [2]; e Butkus et al. [4]. 
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immediate addition of  ice-cold 65% ethanol. The plate was 
placed in a ultrasonic bath for release of cAMP from the 
cells. The cAMP was quantified by a cAMP-specific en- 
zyme immunoassay system (Amersham International, 
Bucks,, UK). 
2.5. Synthesis of collagen in calvarial bone 
The assay for the synthesis of bone collagen was carried 
out by a previously published method [21]. Calvariae 
obtained from 4-day-old ddY mice were precultured in 
modified BGJb medium with 4 m g / m l  BSA for 3 h. Three 
pieces of  bone per flask were then transferred randomly to 
flasks of  fresh medium that contained test samples and 
incubated on a shaker (60 oscillations/min) for 4 days. 
The medium was changed every day. The bones were 
pulse-labeled with L-[2,3-3H]proline at 0.37 M B q / m l  (999 
M B q / m m o l ;  Amersham Japan) during the last 2 h of 
culture. At the end of  culture, the bones were extracted, 
dried, weighed and homogenized. An aliquot of  the ho- 
mogenate was incubated with highly purified bacterial 
collagenase (form III from Clostridium histolyticum; Ad- 
vance Biofactures, Lynbrook, NY). The amounts of radio- 
labeled proline that had been incorporated into collage- 
nase-digestible (CDP) and non-collagen protein (NCP) 
were determined by the method of  Peterkofsky and Diegel- 
mann [22]. The data were expressed as dpm per microgram 
of  dry weight of  bones. Percent collagen synthesis was 
calculated after multiplying NCP by 5.4 to correct for the 
relative abundance of  proline in collagen and non-collagen 
protein [23]. 
2.6. Statistical analysis 
Statistical evaluations were determined by analysis of 
variance (ANOVA) with multiple comparisons done by the 
method of  Fisher's protected least significant difference. 
Significance of  differences was accepted at P < 0.05. 
3. Results 
The synthetic peptide (STC1-20) was eluted as a single 
peak after HPLC, and the correct anticipated sequence of  
amino acids was determined by direct sequencing of  amino 
acids, 
The effect of  STCI-20 on the formation of osteoclast- 
like TRAP÷MNCs is shown in Fig. 2. Few TRAP÷MNCs 
were observed in the original control culture after 8 days 
(Fig. 2A, 2B). Treatment with hPTH1-34 ( 1 0 - 7 - 1 0  - 10 M) 
caused a dose-dependent increase in the number of the 
cells (Fig. 2A). The effect of STC1-20 was apparent when 
cultures incubated in the ]presence and in the absence of 
hPTH1-34 were compared. No effect of STC1-20 was 
detected at the tested concentrations ( 1 0 - 9 - - 1 0  -13  M) in 
the absence of  hPTH1-34 (Fig. 2B), whereas the synthetic 
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Fig. 2. Effects of hPTHI-34 and/or STCI-20 on the formation of 
TRAP + MNCs from mouse bone marrow cells. 7× 105 bone marrow 
cells per well of a 24-well plate were cultured with various concentrations 
of hPTH1-34 (A), STCI-20 (B) or STC1-20 plus hPTH1-34 at 10 -8 M 
(C). After culture for 8 days, TRAP + MNCs were counted, Each value 
indicates the mean + S.E. of results from 5 wells. Statistical analysis was 
performed in (B) and (C). * P < 0.05. 
peptide inhibited hPTH1-34-dependent increases in the 
number of  TRAP+MNCs.  The increase in the number of 
such cells was significantly reduced by STCI-20 (10 - 1 ° -  
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Fig. 3. Time course of the effects of STC1-20 on the release of 45Ca from 
fetal rat calvariae. Two calvariae per well of a 24-well plate were cultured 
with STC1-20 at 10 - I I  M ( Q )  or with vehicle only ( O )  for 2 - 4  days. 
At each indicated time, the release of 45Ca from the two bones was 
measured, Each value indicates the mean 4- S.E. of results from 5 wells. 
*P  < 0.05. 
10 -12 M) and the maximum response was detected at 
10 -11 M (hPTH1-34 plus STC1-20, 12.8 + 1.5 cells vs. 
hPTH1-34 alone, 21.0 + 2.5 cells per well); (Fig. 2C). 
Fig. 3 shows the time course of the effects of  STC 1-20 
on the rate of  release of radioactivity into the medium 
from calvariae of fetal rats that had been prelabeled with 
45Ca. In control, the rate of  release of  45Ca into the 
medium increased with increasing duration of culture, 
from the second to the fourth day. When the bones were 
cultured with 10-11 M STC 1-20, a significant reduction in 
the rate of  release of  45Ca was observed on the fourth day 
(STC1-20, 13.6 + 1.6% vs. control, 19.1 + 1.7% of 45Ca 
released). STC 1-20 (10 - 10_ 10- 12 M) tended to inhibit the 
release of  45Ca, and the effect was significant at 10- ~ M. 
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Fig. 4. Effects of hPTHI-34 and of STC1-20 in the presence of hPTHI-34 
on the release of 45Ca from fetal rat calvariae. Two calvariae per well of a 
24-well plate were cultured with various concentrations of hPTH 1-34 (A) 
and STC1-20 plus 10 -8 M hPTH1-34 (B) for 2 days. Each value 
indicates the mean 4- S.E. of results from 5 wells. Statistical analysis was 
performed in (B). * P < 0.05. 
Table 1 
Effects of hPTH1-34 and STC1-20 on the incorporation of [ H]proline into collagenase-digestible (CDP) and non-collagen protein (NCP) in calvariae of 
newborn mice 
Treatment (M) Incorporation o f [  3H]prOline ( d p m / / z g  dry wt) 
CDP NCP 
% of collagen synthesized ~ 
Control 
tffqM1-34 
STC 1-20 
12.01 + 0.57 5.81 + 1.20 27.68 4- 0.93 
10 -8 7.16 + 0.53 * * * 7.38 4- 0.67 17.14 4- 2.17 * * 
10 -9 14.27 _+ 1.72 6.42 4- 0.37 27.60 4- 0.24 
10 - I °  13.59 4- 0.96 5.56 + 0.09 31.05 + 2.27 
10- i  I 14.31 _+ 0.60 * 5.55 + 0.36 32.37 4- 1.11 * 
10 -12 17.41 + 1.31 * * 6.77 4- 0.47 32.20 4- 0.30 * * 
10-13 16.09 4- 0.58 * * 6.44 + 0.48 31.44 4- 0.76 * 
Three calvariae per flask were cultured with hPTH1-34 at 10 -8 M or with various concentrations of STC1-20 for 4 days and then pulse-labeled with 
[3H]proline for the last 2 h of culture. Each value indicates the mean + S.E. of results from 5 flasks. 
a The percentage of collagen synthesized was calculated correcting for the relative abundance of proline in CDP vs. NCP as described in Section 2. 
Significantly different from the control: * P < 0.05, * * P < 0.01 and * * * P < 0.001. 
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In two-day cultures of the calvariae, hPTH1-34 ( 1 0  - 7 -  
10 - l°  M) increased the rate of release of 45Ca in a 
dose-dependent manner (Fig. 4A). However, STCI-20 had 
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Fig. 5. Effects of hPTH1-34 and /o r  STC1-20 on the production of cAMP 
in ROS 17/2.8-5 cells. ROS 17/'2.8-5 cells in each well of a 48-well 
plate were stimulated for 5 min with various concentrations of hPTH1-34 
(A), STC1-20 (B) and STC1-20 pills hPTH1-34 at 10 -8 M (C). Levels of 
cAMP were measured by an enzyme immunoassay. Each value indicates 
the mean -I- S.E. of results from 4 wells. Statistical analysis was performed 
in (B) and (C). * P < 0.05. 
an inhibitory effect on the increased release of 45Ca in 
cultures exposed to 10 -8 M hPTH1-34 at the same dose as 
the dose that was effective in the absence of hPTH1-34 
(hPTH1-34 plus STC1-20, 14.1% + 1.9% vs. hPTH1-34 
alone, 22.4 4- 3.4% of 45Ca released) (Fig. 4B). 
The effects of STC1-20 on the formation of cAMP in 
osteoblastic ROS 17/2.8-5 cells were investigated. Addi- 
tion of hPTH1-34 (10-7-10 - l0 M) to the cells elicited an 
increase in levels of cAMP in a dose-dependent manner 
(Fig. 5A), while STCI:20 ( 1 0 - 9 - 1 0  -13  M )  failed to in- 
crease levels of cAMP (Fig. 5B). When STC1-20, at 
different concentrations, was added together with 10 -8 M 
hPTH1-34, a significant inhibition of the accumulation of 
cAMP in response to hPTH1-34 was observed at 10 -1°-  
10 -12 M (Fig. 5C). The maximum effect was seen at 
10 -11 M (hPTH1-34 plus STC1-20, 1.11 + 0.06 pmol vs. 
hPTH1-34 alone, 2.84 4- 0.49 pmol cAMP per well). 
Table 1 summarizes the effects of hPTH1-34 and 
STC1-20 on the synthesis of collagen in calvariae of 
newborn mice. hPTH1-34 (10 -8 M) caused a significant 
decrease in the rate of incorporation of [3H]proline into 
CDP, while labeling of NCP was increased (but not signif- 
icantly). In bones treated with STC1-20, the labeling of 
NCP was slightly increased (but not significantly). By 
contrast, the labeling by proline of CDP was significantly 
increased by STC1-20 (10-11-10 - 13 M), SO that the rela- 
tive level of collagen synthesis in the presence of the 
peptide appeared to be greater than in the control. The 
maximum effect of STC 1-20 on the rate of incorporation 
of [3H]proline into CDP was observed at 10 -12 M (con- 
trol, 12.01 + 0.57 dpm vs. STC1-20, 17.41 4- 1.31 
dpm//xg dry weight). 
4. Discussion 
Evidence from a wide variety of studies suggests that 
osteoclasts are derived from hemopoietic progenitor cells. 
Moreover, it is possible to generate osteoclast-like 
TRAP+MNCs from bone marrow cells in culture by stim- 
ulation with PTH [18]. TRAP+MNCs formed in response 
to osteotropic hormones satisfy most of the criteria for 
osteoclasts [18]. In the study reported here, STC1-20 did 
not have an inductive effect on the formation of such cells 
from murine bone marrow cells, while the peptide inhib- 
ited the response to hPTH1-34 in a number of the cells. It 
is suggested that the differentiation of osteoclasts is regu- 
lated by stromal cells and various humoral factors [18], 
although the details have still been uncertain. The progress 
of study on the cell linage of osteoclasts may be an 
important clue to the elucidation of the effect of STC 1-20 
on the formation of osteoclast-like cells. The bone resorp- 
tion assay seemed to provide evidence for the inhibitory 
effect of STC1-20 on the formation of osteoclast-like cells. 
STC1-20 also slightly decreased bone resorption in the 
absence of hPTH1-34, but an obvious effect was detected 
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after a long culture period (4 days). The delay might have 
been due to the influence of non-PTH factors, for example, 
endogenous prostaglandins (PGs) [24,25]. As Chambers et 
al. [25] pointed out, PGs also exert their bone-resorbing 
activities via increases in levels of cAMP in osteoblasts, as 
does PTH. It seems that the effects of STCI-20 on PTH- 
sensitive systems, as described above, represent indirect 
actions rather than a specific action at the PTH receptor 
because the peptide did not have a pronounced effect on 
hPTH1-34-dependent bone resorption and had only a slight 
effect on PTH-independent, PG-related bone resorption 
[24,25]. It is apparent that cAMP in osteoblasts is an 
important second messenger for PTH [20,26]. PTH stimu- 
lates the accumulation of cAMP in osteoblastic cell lines 
and osteoblasts from rat calvariae [20,26]. Lafeber et al. 
[12] reported that trout STC resembled PTH in its bone-re- 
sorbing effect, even though it did not stimulate 'production 
of cAMP. They suggested that trout STC might lack a 
cAMP-stimulating segment since fragments of PTH can 
induce bone resorption without increasing levels of cAMP 
[12]. In the present study, STC1-20 did not stimulate the 
production of cAMP in ROS 17/2.8-5 cells, as also 
observed in the case of native STC from trout [12] and 
salmon [13]. However, STCI-20 reduced the production of 
cAMP in response to hPTH1-34 in ROS 17/2.8-5 cells. It 
is possible that the activities of STCI-20 on the metabolism 
of mammalian bone are at least partly related to the 
response of cAMP. 
PTH is well known for its bone-catabolic action and 
recent observations suggest that it also has an anabolic 
effect on bone [21,27,28]. Since the effects of STC on 
bone formation had not previously been reported, we 
decided to examine the direct effects of STC1-20 on 
synthesis of bone collage. STC1-20 enhanced synthesis of 
bone collagen specifically, while hPTHI-34 inhibited such 
synthesis, as previously reported [21]. Thus, we found that 
STC1-20 and hPTH1-34 have dissimilar effect on the 
synthesis of bone collagen, as well as on bone resorption. 
These effects of STCI-20 looked like those of calcitonin 
[18,29]. It is improbable that STC 1-20 binds to calcitonin 
receptor, because the homology on constitution is not 
recognized between STC and calcitonin [4]. STC decreases 
calcium levels in blood, although calcitonin seems of 
minor importance as a calcium-regulating factor in fish 
[30]. Moreover, STC receptor has not been cloned even in 
fish. We shall continue to examine this issue in detail. In 
addition, STC1-20 elicited biphasic concentration-depend- 
ency in the present assay systems. Biphasic effects of 
PGE 2 on bone formation have been also reported [31]. In 
this case, it was indicated [31] that the biphasic activities 
of PGE 2 might have been due to the presence of two types 
of cell. There is also the possibility of the presence of 
different kinds of targets in response to STC1-20 in the 
light of diverse effects of the peptide on mammalian 
systems. 
STC has no amino acid sequence homology to other 
known vertebrate or invertebrate peptides, including PTH 
[4]. Nevertheless, it seems that STC and material from the 
CS show marked similarity, in terms of bioactivity, to 
mammalian PTH in both mammalian [8,11,12] and 
teleostean assay systems [32]. However, there is still some 
controversy as to whether STC is identical to a PTH-like 
substance of the CS. In fact, PTH does not cross-react with 
antiserum against STC secreted from primary cultures of 
trout CS cells [33]. Stern et al. [13] reported that purified 
STC from coho salmon had no effects in several kinds of 
fetal bone. One plausible explanation for these differences 
is that the tertiary structure of the STC molecule might 
react to PTH-sensitive systems. Milliken et al. [15] re- 
ported that the C-terminal fragment of eel STC (peptide 
W) enhanced whole-body calcium uptake in trout fry. The 
work of Fenwick and Verbost suggests that peptide W 
reduces the uptake of calcium by stanniectomized eel and 
that the difference between the effects of peptide W on 
calcium uptake in trout and eel lies in the origin of the 
peptide [17]. It is, indeed, clear that the C-terminal end of 
STC differs between Australian eel [4] and coho salmon 
[5]. In our experiments, moreover, the N-terminal peptide 
fragment of STC did not have a PTH-like activity in 
mammalian systems. Thus, the expression of PTH-like 
activities of STC might be dependent on the amino-acid 
sequence at the C-terminal end. As a possible explanation 
for the various bioactivities of STC in mammals as well as 
teleosts, it is not impossible that there are several active 
sites in the entire STC molecule. Studies of the other 
peptide fragments of STC will clearly be of interest. 
In conclusion, our results suggest that the highly con- 
served amino-terminal region of STC from teleosts has 
diverse effects, of a biphasic nature, on the metabolism of 
mammalian bone and that the effects of the amino-terminal 
peptide are different from those of the amino-terminal 
fragment of hPTH. It is likely that the main active portion 
of the molecule might be related to the region with a high 
degree of amino acid sequence conservation. Therefore, 
our observations will be useful in further attempts to 
define the bioactivity of STC. 
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